Dr. Zhoumeng Lin
Conventional anti-cancer drugs have several limitations, including damage on healthy cells and inability to enter the core of tumor tissues, resulting in side effects, reduced efficacies, and low survival rates. Recent advancements in nanotechnology have made it possible to design nanomaterials-based carriers (nanocarriers) of anti-cancer drugs for delivery to tumor tissues selectively. A comprehensive understanding of the distribution of anti-cancer drug nanocarriers in the body is thus important for proper risk assessment and safe applications of these new materials. Many anti-cancer drug nanocarriers have been shown to be effective in reducing tumor sizes in laboratory animals, and some are effective in human clinical trials.
My research is to develop computer models to simulate and predict the distribution of new anti-cancer drug nanocarriers in the body of laboratory animals and humans. The model simulation results will improve our understanding of how much of the administered anti-cancer drug nanocarriers reach the tumor and healthy tissues. These results will help other researchers assess possible risk of these new materials properly and to apply them safely.